- Home
- CBC vs TGTX Comparison
CBC vs TGTX Comparison
Compare CBC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBC | TGTX |
|---|---|---|
| Founded | 1902 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.9B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | CBC | TGTX |
|---|---|---|
| Price | $23.94 | $27.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.88 | ★ $49.80 |
| AVG Volume (30 Days) | 317.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $12.05 | $48.75 |
| Revenue Next Year | $6.35 | $25.01 |
| P/E Ratio | $14.38 | ★ $9.72 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.50 | $25.37 |
| 52 Week High | $25.50 | $46.48 |
Technical Indicators
Market Signals| Indicator | CBC | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 39.82 |
| Support Level | $23.28 | $27.51 |
| Resistance Level | $24.69 | $32.77 |
| Average True Range (ATR) | 0.63 | 1.15 |
| MACD | -0.05 | -0.22 |
| Stochastic Oscillator | 37.68 | 19.31 |
Price Performance
Historical ComparisonAbout CBC Central Bancompany Inc.
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.